Voxelotor (GBT440), a first‐in‐class hemoglobin oxygen‐affinity modulator, has promising and reassuring preclinical and clinical data
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25042
Abstract: Voxelotor, a first-in-class drug, is currently being studied for the treatment of sickle cell disease in the United States and Europe that has received Breakthrough Therapy Designation (BTD) by the Food and Drug Administration (FDA)… read more here.
Keywords: hemoglobin; affinity; voxelotor; first class ... See more keywords
Voxelotor in sickle cell disease
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26549
Abstract: A 45-year-old woman with sickle cell/ß thalassemia due to the HBB :c.92 + 5G>C severe ß + thalassemia mutation, who had been on a clinical trial of voxelotor for 4 years was assessed clinically and… read more here.
Keywords: cell; voxelotor; sickle; cell disease ... See more keywords
Identification of human in vitro metabolites of the haemoglobin S polymerization inhibitor voxelotor for doping control purposes.
Sign Up to like & getrecommendations! Published in 2023 at "Drug testing and analysis"
DOI: 10.1002/dta.3489
Abstract: Voxelotor (GBT440) is a haemoglobin S polymerization inhibitor used to treat anaemia in sickle cell disease. Due to an increase of arterial oxygen saturation as well as serum erythropoietin and haemoglobin, the World Anti-Doping Agency… read more here.
Keywords: vitro metabolites; haemoglobin polymerization; doping control; polymerization inhibitor ... See more keywords
Hb S (HBB: c.20A>T) Characteristics by High Performance Liquid Chromatography in Patients with Sickle Cell Disease Receiving the Novel Agent Voxelotor.
Sign Up to like & getrecommendations! Published in 2021 at "Hemoglobin"
DOI: 10.1080/03630269.2020.1788074
Abstract: Voxelotor is a novel agent in the management of sickle cell disease. It is an inhibitor of Hb S (HBB: c.20A>T) polymerization that reversibly binds to hemoglobin (Hb), stabilizing it in the oxygenated state that… read more here.
Keywords: voxelotor; cell disease; novel agent; hbb 20a ... See more keywords
Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2031967
Abstract: ABSTRACT Background Sickle cell disease (SCD) is a genetic disease that impacts patients’ quality of life, healthcare costs, and life expectancy. Elevated sickle hemoglobin (HbS), which readily polymerizes, causes red blood cell sickling, leading to… read more here.
Keywords: cell; voxelotor; real world; cell disease ... See more keywords
Voxelotor for the treatment of sickle cell disease in pediatric patients
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2082408
Abstract: ABSTRACT Introduction Sickle cell disease (SCD) describes a group of heritable blood disorders caused by the polymerization of sickle hemoglobin (HbS). HbS polymerization leads to anemia and vaso-occlusion, a process that impedes delivery of oxygen… read more here.
Keywords: voxelotor; cell disease; pediatric patients; treatment ... See more keywords
Alterations of Hemoglobin Fractionation in a Sickle Cell Disease Patient on Voxelotor Therapy
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqaa161.220
Abstract: Voxelotor is a molecule that allosterically binds to the alpha-chain of hemoglobin, resulting in increased oxygen affinity. This allosteric inhibition leads to prevention of hemoglobin polymerization and sickling of red blood cells in response to… read more here.
Keywords: fractionation; treatment; voxelotor; therapy ... See more keywords
Spotlight Commentary – Voxelotor: A new kid on the block in the treatment of sickle cell disease
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15249
Abstract: Sickle cell disease (SCD) is a common inherited disorder, which is caused by a mutation in the haemoglobin β subunit gene that results in the formation of sickle haemoglobin (HbS). On deoxygenation, HbS polymerizes, that… read more here.
Keywords: cell; pharmacology; voxelotor; sickle ... See more keywords
Effects of GBT1118, a voxelotor analog, on intestinal pathophysiology in sickle cell disease.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of haematology"
DOI: 10.1111/bjh.18813
Abstract: Voxelotor is an allosteric haemoglobin (Hb) modulator that binds covalently and reversibly to Hb alpha chain to facilitate improved Hb-O2 affinity and arterial oxygen. It, therefore, reduces the susceptibility of erythrocytes carrying Haemoglobin S to… read more here.
Keywords: effects gbt1118; voxelotor; intestinal pathophysiology; cell disease ... See more keywords
Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13830
Abstract: The use of blood transfusions to improve anemia resulting from sickle cell disease (SCD) is often limited by alloimmunization, which occurs due to exposure to incompatible antigen present on donor red blood cells (RBCs). This… read more here.
Keywords: use voxelotor; voxelotor; cell disease; use ... See more keywords
Patient perception of voxelotor treatment benefit in sickle cell disease
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Investigative Medicine"
DOI: 10.1136/jim-2021-002215
Abstract: Patients with sickle cell disease (SCD) experience a range of clinical symptoms, including acute and chronic pain, fatigue, and respiratory problems, as well as chronic organ complications that can lead to disability and accelerated mortality.… read more here.
Keywords: voxelotor treatment; voxelotor; cell disease; treatment ... See more keywords